Literature DB >> 17592021

Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer.

A Stigliano1, O Gandini, L Cerquetti, P Gazzaniga, S Misiti, S Monti, A Gradilone, P Falasca, M Poggi, E Brunetti, A M Aglianò, V Toscano.   

Abstract

The metastatic lymph node 64 (MLN64), which is localized in the human chromosome 17, encodes a protein with strong homology with steroidogenic acute regulatory protein. Its overexpression in human breast carcinomas and MLNs led to the hypothesis that this protein could be involved in intraneoplastic steroidogenesis. In the present study, we investigated the expression of MLN64 in prostate cancer, another hormone-dependent tumor, and compared its expression with that of CYP17, the gene encoding for the key enzyme of androgen synthesis. We investigated by RT-PCR the expression of MLN64 and CYP17 in 60 prostatic tumors and compared their expression with the stage of disease and the appearance of relapses in a follow-up of 24 months. We found MLN64 and CYP17 expressed in all samples examined, with significantly higher expression in neoplastic tissues with respect to normal tissues (NTs). Moreover, only in neoplastic but not in NTs, a positive linear correlation was found between MLN64 and CYP17 gene expression. MLN64 and CYP17 expression seems to correlate with high stage, high Gleason score and short relapse-free time. These data, for the first time, demonstrate the presence of MLN64 and CYP17 expression in both normal and neoplastic prostatic tissues. The biological role of MLN64 in human prostate and, particularly, in neoplastic tissue is still unclear. Our findings concerning MLN64 and CYP17 gene expression and their significant positive correlation in human prostate cancer may suggest their possible role in intraneoplastic autonomous steroidogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592021     DOI: 10.1677/JOE-07-0131

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  16 in total

1.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

Review 2.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

Review 3.  ER-endosome contact sites: molecular compositions and functions.

Authors:  Camilla Raiborg; Eva M Wenzel; Harald Stenmark
Journal:  EMBO J       Date:  2015-06-03       Impact factor: 11.598

Review 4.  Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function.

Authors:  Laura A Martin; Barry E Kennedy; Barbara Karten
Journal:  J Bioenerg Biomembr       Date:  2014-11-26       Impact factor: 2.945

5.  First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent.

Authors:  Margherita Lapillo; Barbara Salis; Stefano Palazzolo; Giulio Poli; Carlotta Granchi; Filippo Minutolo; Rossella Rotondo; Isabella Caligiuri; Vincenzo Canzonieri; Tiziano Tuccinardi; Flavio Rizzolio
Journal:  ACS Med Chem Lett       Date:  2019-02-20       Impact factor: 4.345

Review 6.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

Review 7.  CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.

Authors:  Anitha B Alex; Sumanta K Pal; Neeraj Agarwal
Journal:  Ther Adv Med Oncol       Date:  2016-04-19       Impact factor: 8.168

Review 8.  Innovations in the systemic therapy of prostate cancer.

Authors:  Dale R Shepard; Derek Raghavan
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

9.  Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?

Authors:  Emmanuel S Antonarakis; Mario A Eisenberger
Journal:  Nat Clin Pract Oncol       Date:  2008-10-28

Review 10.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.